Connect with us

Business

John Deere faces a crossroads amid decreasing demand, increasing investments

Published

on

John Deere faces a crossroads amid decreasing demand, increasing investments


Attendees view a John Deere 7R 270 row crop tractor at the Deere & Co. booth during the World Ag Expo at the International Agri-Center in Tulare, California on February 11, 2025.

Patrick T. Fallon | AFP | Getty Images

John Deere is facing a crossroads as the company continues to see weaker demand in the agricultural sector even while it has committed to investing millions in U.S. manufacturing and promised a brighter road ahead.

The agricultural machinery company warned on its fiscal third-quarter earnings call last week that it is seeing much softer demand, posting significant year-over-year decreases in net income and sales.

The company is working to position itself in the larger agricultural sector, which has seen growing challenges with rising costs, climate change impacts, labor shortages and more.

Farmers have also been dealing with lower prices on crops like corn and grain and have pared back their spending as a result. In turn, Deere’s target audience has pulled back on its willingness to buy new agricultural equipment.

Deere has also been hit by tariff costs, estimating that it could take a $600 million hit for the fiscal 2025 year. The company has already seen $300 million in tariff expenses year to date.

Just after reporting its earnings, the company confirmed to CNBC that it announced 238 layoffs across its Illinois and Iowa factories, adding to thousands who have been laid off over the past year. The company cited decreased demand and lower order volumes as the main factors behind the job reductions.

“As stated on our most recent earnings call, the struggling ag economy continues to impact orders for John Deere equipment,” Deere told CNBC in a statement. “This is a challenging time for many farmers, growers and producers, and directly impacts our business in the near term.”

The manufacturer employs more than 70,000 people globally.

Still, Deere has identified enough green shoots to point to a less-troubling future.

On its most recent earnings call, company executives emphasized the growth in demand in both Europe and South America after seeing weakness in North America. Despite macroeconomic headwinds, Deere’s president of its worldwide agriculture and turf division said the company remains confident in its future.

“We think there’s positive tail winds from both what we see in the trade deals, and we think there are positive tail winds from what we see in tax policy,” Cory Reed said on the call.

And in June, the company released a statement that “myth busted” any claims that Deere might need to shut down its U.S. manufacturing due to the fall in demand. Instead, the company said it was making a “bold move” to invest $20 billion into U.S. manufacturing over the next 10 years.

It follows a similar string of announcements from companies trying to shore up their “Made in the USA” bona fides since President Donald Trump took office. Before the election, Trump threatened Deere with 200% tariffs if it moved production to factories in Mexico.

“Over the next decade, we will continue to make significant investments in our core U.S. market,” CEO John May said in the statement in June. “This underscores our dedication to innovation and growth while staying cost-competitive in a global market.”

What Wall Street is saying

Despite the struggles in the broader agricultural sector, Wall Street analysts on the whole remain optimistic about Deere’s road ahead.

Oppenheimer analyst Kristen Owen wrote last week that she remains bullish on Deere and expects increased confidence into 2026, telling CNBC that she believes the company is taking an “appropriately cautiously optimistic outlook.”

Even Truist analyst Jamie Cook, who lowered his target after Deere’s earnings last week and emphasized an uncertain outlook for 2026, said he still believes this year marks a bottoming for the company’s earnings per share.

The company’s stock has seen a nearly 30% increase over the one-year period.

Stock Chart IconStock chart icon

Deere stock

Looking at Deere’s history and the hit that the farming industry has taken over the past few years, D.A. Davidson analyst Michael Shlisky told CNBC he can’t imagine the company going much lower from here.

“The way I’d say it is 2025 could be the worst, the lowest number of tractor sales in the history of modern agriculture,” he said, with the potential for the trend to swing upward becoming imminent.

While the optimism might not be directly translating to sales today, Shlisky said the “hints” of progress are enough to make him excited about the company’s future, including the growth in Europe and South America.

“When parts of the world are doing better, the parts that aren’t doing as well are likely to follow,” Shlisky said.

While not commenting directly on the latest round of layoffs, Shlisky said he doesn’t think investors would be surprised to see the necessary cost-cutting measures at this point in the company’s trajectory.

Similarly, Morgan Stanley analysts wrote in a note that while demand may be decreasing, they stand behind a thesis that Deere earnings have bottomed and that the company remains an “attractive opportunity longer term.”

Analyst Angel Castillo told CNBC that Deere and the agricultural sector at large are cyclical, so while the short-term remains uncertain, the long-term outlook for the company is likely to bounce back, noting that precision agriculture in particular is likely to take off.

“This is one of the unique areas where we think even if there’s more challenges next year, as we kind of expect, the earnings downside risk is much more de-risked or already captured by expectation,” Castillo said.

With its latest cost-cutting measures, Deere is saving itself by not overproducing or creating a supply chain issue, Castillo added.

“The reality today is that we’re still in an uncertain environment, and I think they’re managing in a disciplined, rational way to try to make sure not to create a worse environment,” he said.

Oppenheimer's Kristen Owen gives her read on Deere post-earnings

Don’t miss these insights from CNBC PRO



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Indigo Shares Decline Over 4% On Promoter Offloading Stake

Published

on

Indigo Shares Decline Over 4% On Promoter Offloading Stake


Mumbai: The shares of InterGlobe Aviation, the parent company of IndiGo Airlines, tanked over 4 per cent in the early trading on Thursday on news of promoter Rakesh Gangwal’s family selling stocks worth Rs 7,085 crore through a block deal.  

At around 11:38 am, the shares were trading at Rs 5,789.0, down 4.31 per cent or Rs 261.

The promoter family is likely to sell 1.2 lakh shares, worth Rs 7,085 crore, at an average price of Rs 5,830 per share.

Add Zee News as a Preferred Source


(Also Read: Key Financial Rules Changing From September 2025)

 

According to earlier media reports, the Gangwal family plans to sell up to 3.1 per cent of InterGlobe Aviation through block deals valued at approximately Rs 7,020 crore.

A floor price of Rs 5,808 per share, or about 4 per cent less than the closing price of the previous session, was anticipated for the block deal.

With this, the family’s persistent withdrawal from IndiGo continues.

They have been reducing their stake in the airline since Rakesh Gangwal left the board in February 2022; as of 2025, they have sold almost 9 per cent of the company.

(Also Read: What Is GST Compensation Cess? GST Council May End It By October 31)

By reducing their ownership of InterGlobe Aviation, Rakesh Gangwal and his family have raised more than Rs 45,300 crore since 2022.

In September 2022, a 2.74 per cent stake worth Rs 2,005 crore was sold. In February 2023, his wife, Shobha Gangwal, sold a 4 per cent stake for Rs 2,944 crore, and in August 2023, a further 2.9 per cent stake was sold for slightly more than Rs 2,800 crore.

Despite a 4.7 per cent increase in revenue, IndiGo recently reported a 20 per cent year-over-year drop in net profit for the first quarter of FY26, with earnings of Rs 2,176 crore.

Higher fuel prices, exchange rate fluctuations, and other external factors were the primary causes of the decline in profitability.

However, the airline continued to demonstrate strong operational performance, as evidenced by its 84.2 per cent passenger load factor and 87.1 per cent on-time performance.



Source link

Continue Reading

Business

Top stocks to buy today: Stock recommendations for August 28, 2025 – check list – The Times of India

Published

on

Top stocks to buy today: Stock recommendations for August 28, 2025 – check list – The Times of India


Top stocks to buy today (AI image)

Top stock market recommendations: According to Aakash K Hindocha, Deputy Vice President – WM Research, Nuvama Professional Clients Group, Nykaa, Kaynes, and Dr Reddy’s Laboratories are the top buy calls for today. Here’s his view on Nifty, Bank Nifty and the top stock picks for August 28, 2025:Index View: NiftyAfter an inside bar formation on Monday, Nifty opened with a gap down reeling all throughout the session ahead of its trading holiday on Wednesday. The index has closed below its trailing support of 24800 allowing for further downside to be opened for 24500 / 24350. Nifty has also formed a bearish head and shoulders formation on daily charts with a neck line support seen at 24450. A break below the same post monthly expiry could reel in further pressure on the index.Bank NiftyUnderperforming Nifty, Bank has broken its support of 55050 opening for a test of sub 54000 odd levels to begin with. The index has also closed at a 3.5 month low on daily charts ahead of its monthly expiry scheduled on Thursday. 55000 is likely to act as resistance on the upside while the index slides below sub 54000 levels in the coming week.NYKAA (BUY):

  • LCP: 231.65
  • Stop Loss: 223
  • Target: 252

Stock has been gaining traction ever since its 3 year triangle breakout seen in June 2025. For now NYKAA has given the highest ever close in past 3 years of trading along with a huge cup and handle breakout on daily and weekly charts. This opens up for a 18-20% trading buy target on the stock, yet we would advise for an initial uptick being 250+ on this leg.KAYNES (BUY):

  • LCP: 6197
  • Stop Loss: 5980
  • Target: 6620

After a cup and handle breakout in early August 2025, stock has been consolidating near the breakout zone for the past 4 weeks now. Last week’s price action suggests further move northwards from CMP as the stock has completed multiple retests of its ongoing breakout.Dr Reddy’s Laboratories (BUY):

  • LCP: 1263
  • Stop Loss: 1230
  • Target: 1355

Sustaining above its 200 DMA support, DRREDDY’s has also given a bullish flag breakout on daily charts. This allows its initial upside to open for the 1350-1360 zone where it could meet another potential breakout on upside.(Disclaimer: Recommendations and views on the stock market and other asset classes given by experts are their own. These opinions do not represent the views of The Times of India)





Source link

Continue Reading

Business

White House fires CDC director Monarez after she refuses to resign; 4 top health officials quit

Published

on

White House fires CDC director Monarez after she refuses to resign; 4 top health officials quit


Susan Monarez, President Donald Trump’s nominee to be the Director of the Centers for Disease Control and Prevention (CDC), testifies during her confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions in the Dirksen Senate Office Building on June 25, 2025 in Washington, DC.

Kayla Bartkowski | Getty Images

The White House on Wednesday said it had fired Centers for Disease Control and Prevention Director Susan Monarez after she refused to resign. Four other top CDC officials announced they were quitting the embattled health agency.

The leadership crisis at CDC erupted the same day the Food and Drug Administration announced new limits on who can get the latest approved round of Covid vaccines in the U.S.

“Susan Monarez is not aligned with the President’s agenda of Making America Healthy Again,” White House Spokesman Kush Desai said in a statement to NBC News. “Since Susan Monarez refused to resign despite informing [Health and Human Services Department] leadership of her intent to do so, the White House has terminated Monarez from her position with the CDC.”

The statement comes hours after attorney Mark Zaid said he was representing Monarez and that she had not actually been fired yet or stepped down, adding that she would not resign.

“When CDC Director Susan Monarez refused to rubber-stamp unscientific, reckless directives and fire dedicated health experts, she chose protecting the public over serving a political agenda,” Zaid said in a statement. “For that, she has been targeted.”

Earlier on Wednesday, HHS said in a post on X that “Monarez is no longer director” of the agency. 

Monarez, a longtime federal government scientist, was sworn in on July 31. She is the first CDC director to be confirmed by the Senate following a new law passed during the pandemic that required lawmakers to approve nominees for the role.

The Washington Post first reported her ousting on Wednesday. 

At least four other officials also submitted their resignations on Wednesday in a massive shakeup at the agency: Dr. Debra Houry, the CDC’s chief medical officer; Dr. Demetre Daskalakis, director of the National Center for Immunization and Respiratory Diseases; Dr. Daniel Jernigan, the director of the National Center for Emerging and Zoonotic Infectious Diseases; and Dr. Jennifer Layden, director of the Office of Public Health Data, Surveillance and Technology.

Houry, in a resignation letter obtained by NBC News, wrote about the dangers of the spread of vaccine misinformation and said proposed budget cuts and reorganization plans would negatively impact the CDC’s ability to address conditions like hypertension, diabetes, cancer, overdoses and mental health issues.

In his resignation letter, also obtained by NBC News, Daskalakis said he was leaving the agency “because of the ongoing weaponizing of public health.”

Her departure comes at a tumultuous time for the agency, which is reeling from a gunman’s attack on its Atlanta headquarters on Aug. 8. A police officer died in the shooting. 

Monarez on Friday canceled a meeting with CDC workers that had been scheduled for Monday, according to an email obtained by NBC News. She said she wanted to assure staff that the agency is working to restore their “trust in the safety and security of all CDC workplaces.”

President Donald Trump nominated Monarez after withdrawing his first pick to lead the CDC, former Republican congressman Dave Weldon, hours before his confirmation hearing. Weldon has been criticized for his views on vaccines

— CNBC’s Michele Luhn contributed to this report.



Source link

Continue Reading

Trending